| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 90999 |
Unlisted dialysis procedure, inpatient or outpatient |
125,083 |
10,031 |
$3.89M |
| 83970 |
|
5,944 |
5,048 |
$742K |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
106,173 |
6,591 |
$692K |
| 82728 |
|
5,609 |
4,804 |
$643K |
| 83550 |
|
5,386 |
4,547 |
$370K |
| 83540 |
|
5,906 |
4,978 |
$303K |
| J0887 |
Injection, epoetin beta, 1 microgram, (for esrd on dialysis) |
2,021 |
1,105 |
$106K |
| 82108 |
|
485 |
430 |
$94K |
| J1756 |
Injection, iron sucrose, 1 mg |
19,190 |
5,334 |
$80K |
| A4657 |
Syringe, with or without needle, each |
6,131 |
5,258 |
$26K |
| J0604 |
Cinacalcet, oral, 1 mg, (for esrd on dialysis) |
3,054 |
1,229 |
$24K |
| J1270 |
Injection, doxercalciferol, 1 mcg |
27,004 |
2,422 |
$14K |
| 90970 |
|
1,269 |
48 |
$10K |
| 85041 |
|
5,505 |
4,603 |
$6K |
| 90677 |
|
36 |
35 |
$4K |
| 85048 |
|
5,426 |
4,570 |
$4K |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
3,322 |
2,276 |
$4K |
| J0636 |
Injection, calcitriol, 0.1 mcg |
3,046 |
203 |
$3K |
| 91320 |
|
17 |
17 |
$2K |
| 90945 |
|
594 |
30 |
$2K |
| 86706 |
|
88 |
83 |
$164.87 |
| 87340 |
|
87 |
83 |
$158.55 |
| G0008 |
Administration of influenza virus vaccine |
322 |
297 |
$63.89 |
| 90662 |
|
140 |
134 |
$0.00 |
| J1644 |
Injection, heparin sodium, per 1000 units |
4,141 |
344 |
$0.00 |
| 90670 |
|
58 |
49 |
$0.00 |
| 0124A |
|
22 |
22 |
$0.00 |
| 90480 |
|
17 |
17 |
$0.00 |
| 90674 |
|
155 |
145 |
$0.00 |
| 0064A |
|
34 |
33 |
$0.00 |
| G0009 |
Administration of pneumococcal vaccine |
27 |
27 |
$0.00 |
| 82607 |
|
60 |
49 |
$0.00 |
| 0011A |
|
17 |
17 |
$0.00 |
| 90747 |
|
12 |
12 |
$0.00 |
| 0012A |
|
16 |
15 |
$0.00 |